Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer

被引:8
作者
Broughman, James R. [1 ]
Vuong, Winston [1 ]
Mian, Omar Y. [1 ]
机构
[1] Cleveland Clin, Taussig Canc Inst, Dept Radiat Oncol, 9500 Euclid Ave,CA-50, Cleveland, OH 44195 USA
基金
美国国家卫生研究院;
关键词
Bladder cancer; Radiation therapy; Bladder preservation; Urothelial Cancer; LONG-TERM OUTCOMES; COMBINED-MODALITY TREATMENT; COMBINED RADIATION-THERAPY; QUALITY-OF-LIFE; RADICAL CYSTECTOMY; TRANSURETHRAL SURGERY; UROTHELIAL CARCINOMA; PRESERVATION; RADIOTHERAPY; TRIAL;
D O I
10.1007/s11864-020-00800-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Opinion statement Although radical cystectomy is considered the gold standard approach for patients with muscle-invasive bladder cancer, tri-modal therapy (TMT) is a well-tolerated and efficacious alternative to radical cystectomy that is underutilized in inoperable patients and rarely offered to cystectomy candidates in the USA. Retrospective data suggest similar outcomes between radical cystectomy and TMT after adjusting for patient selection and other confounding factors. Nearly 70-80% of patients can keep their native bladder with favorable post-treatment quality of life metrics. Current trials are investigating novel combination strategies including immune checkpoint inhibition along with chemoradiation or radiation. Emerging techniques for improved patient selection and risk stratification include incorporating MP-MRI, and novel biomarkers such as inflammatory, stromal, and DNA damage response gene signatures may guide patient selection and expand the landscape of bladder preservation options available to patients in the future.
引用
收藏
页数:10
相关论文
共 46 条
  • [1] Radical Cystectomy versus Bladder-Preserving Therapy for Muscle-Invasive Urothelial Carcinoma: Examining Confounding and Misclassification Biasin Cancer Observational Comparative Effectiveness Research
    Bekelman, Justin E.
    Handorf, Elizabeth A.
    Guzzo, Thomas
    Pollack, Craig Evan
    Christodouleas, John
    Resnick, Matthew J.
    Swisher-McClure, Samuel
    Vaughn, David
    Ten Have, Thomas
    Polsky, Daniel
    Mitra, Nandita
    [J]. VALUE IN HEALTH, 2013, 16 (04) : 610 - 618
  • [2] Long-term Outcomes and Patterns of Failure Following Trimodality Treatment With Bladder Preservation for Invasive Bladder Cancer
    Buchser, David
    Zapatero, Almudena
    Rogado, Jacobo
    Talaya, Marisol
    Martin de Vidales, Carmen
    Arellano, Ramon
    Bocardo, Gloria
    Cruz Conde, Alfonso
    Perez, Leopoldo
    Murillo, Maria T.
    [J]. UROLOGY, 2019, 124 : 183 - 189
  • [3] Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy
    Canter, Daniel
    Long, Christopher
    Kutikov, Alexander
    Plimack, Elizabeth
    Saad, Ismail
    Oblaczynski, Megan
    Zhu, Fang
    Viterbo, Rosalia
    Chen, David Y. T.
    Uzzo, Robert G.
    Greenberg, Richard E.
    Boorjian, Stephen A.
    [J]. BJU INTERNATIONAL, 2011, 107 (01) : 58 - 62
  • [4] Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
    Chang, Sam S.
    Bochner, Bernard H.
    Chou, Roger
    Dreicer, Robert
    Kamat, Ashish M.
    Lerner, Seth P.
    Lotan, Yair
    Meeks, Joshua J.
    Michalski, Jeff M.
    Morgan, Todd M.
    Quale, Diane Z.
    Rosenberg, Jonathan E.
    Zietman, Anthony L.
    Holzbeierlein, Jeffrey M.
    [J]. JOURNAL OF UROLOGY, 2017, 198 (03) : 552 - 559
  • [5] MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer
    Choudhury, Ananya
    Nelson, Louisa D.
    Teo, Mark T. W.
    Chilka, Sameer
    Bhattarai, Selina
    Johnston, Colin F.
    Elliott, Faye
    Lowery, Johanna
    Taylor, Claire F.
    Churchman, Michael
    Bentley, Johanne
    Knowles, Margaret A.
    Harnden, Patricia
    Bristow, Robert G.
    Bishop, D. Timothy
    Kiltie, Anne E.
    [J]. CANCER RESEARCH, 2010, 70 (18) : 7017 - 7026
  • [6] Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712A Randomized Phase II Trial
    Coen, John J.
    Zhang, Peixin
    Saylor, Philip J.
    Lee, Cheryl T.
    Wu, Chin-Lee
    Parker, William
    Lautenschlaeger, Timothy
    Zietman, Anthony L.
    Efstathiou, Jason A.
    Jani, Ashesh B.
    Kucuk, Omer
    Souhami, Luis
    Rodgers, Joseph P.
    Sandler, Howard M.
    Shipley, William U.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (01) : 44 - +
  • [7] Radiotherapy for muscle-invasive carcinoma of the bladder: Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy
    Cowan, RA
    McBain, CA
    Ryder, WDJ
    Wylie, JP
    Logue, JP
    Turner, SL
    Van Der Voet, J
    Collins, CD
    Khoo, VS
    Read, GR
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01): : 197 - 207
  • [8] Cuellar MA, 2020, J CLIN ONCOL, V38
  • [9] EAU Guidelines, EAU ANN C COP
  • [10] Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Efstathiou, Jason A.
    Mouw, Kent W.
    Gibb, Ewan A.
    Liu, Yang
    Wu, Chin-Lee
    Drumm, Michael R.
    da Costa, Jose Batista
    du Plessis, Marguerite
    Wang, Natalie Q.
    Davicioni, Elai
    Feng, Felix Y.
    Seiler, Roland
    Black, Peter C.
    Shipley, William U.
    Miyamoto, David T.
    [J]. EUROPEAN UROLOGY, 2019, 76 (01) : 59 - 68